To the Editor Mailankody and Prasad1 identify many important cancer treatments approved by the Food and Drug Administration. However, by failing to account for the complex and variable ways progress occurs, as well as the role of discounts in market-based pricing, the analysis does not provide enough information to correlate clinical value and price.
Burkholder R. Pricing and Value of Cancer Drugs. JAMA Oncol. 2015;1(6):841–842. doi:10.1001/jamaoncol.2015.1962
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: